Celltrion

Market position

Celltrion presents itself as the largest manufacturer and exporter of biosimilars in Korea and is described in secondary sources as one of the world's largest biosimilar manufacturers, having launched the world's first monoclonal antibody biosimilar and the first EC-approved omalizumab biosimilar. Its founder Seo Jung-jin has been reported by Forbes as Korea's richest person and was named EY World Entrepreneur Of The Year in 2021.

Differentiators cited include first-mover status in monoclonal antibody biosimilars, an integrated in-house model spanning R&D, clinical trials, regulatory affairs, 250,000-litre manufacturing capacity and direct distribution, first-to-market positions in specific molecules (first subcutaneous infliximab approved by the FDA; first EC-approved anti-IgE antibody biosimilar), breadth of dose strengths and device presentations, and reinvestment of roughly 20% of revenue into R&D with about 30% of employees in R&D roles.

Technology

Celltrion's platform is based on CHO mammalian cell culture production of monoclonal antibodies, with animal cell culture and downstream process facilities designated as "National Core Technology" in Korea and certified under US FDA cGMP and EU EMA GMP. Novel-drug technology efforts centre on a next-generation ADC platform using the PBX-7016 payload (reported low toxicity and high tumour growth inhibition), dual-payload ADCs combining complementary mechanisms of action, and conditionally-active and immuno-oncology multispecific antibodies designed to improve tumour selectivity and reduce on-target off-tumour toxicity. The company also develops alternative formulations, notably subcutaneous infliximab (Remsima SC / Zymfentra).

Go-to-market

The company built and expanded a direct sales organisation in major markets including the United States and Europe, following an earlier model in which marketing arm Celltrion Healthcare handled worldwide distribution through regional partners such as Hospira, Nippon Kayaku, Egis, Mundipharma, Biogaran and Kern. Celltrion Healthcare was merged into Celltrion in December 2023. Product launches are staged by dose strength and device format — for example, Omlyclo 75 mg and 150 mg in Europe in late 2024 followed by the 300 mg strength in Germany, the UK and France in 2025 — and the company acquired the Swiss distributor iQone Healthcare to strengthen European channels.

Patients, prescribing healthcare professionals, hospitals and healthcare institutions, and public/tender purchasers in the roughly 100 countries where its products are approved; also pharmaceutical companies purchasing contract manufacturing services.

Geography

Headquartered in Incheon, South Korea, with products distributed in approximately 100 countries. It operates subsidiaries and operations across Europe, Asia and the Americas, including Celltrion USA (established 2018), Celltrion Vietnam Corporation (established September 30, 2024), the acquired Swiss distributor iQone Healthcare, and a drug substance manufacturing site in Branchburg, New Jersey acquired from Eli Lilly. Key European commercial markets include Germany, the UK and France.

History

After its 2002 founding, Celltrion initially operated as a contract manufacturer, signing a supply agreement with Bristol-Myers Squibb in 2005, completing its first 50,000-litre plant the same year and receiving US FDA cGMP approval for it in 2007. It listed on the Korea Exchange in 2008 and entered a global distribution agreement with Nexol, which was renamed Celltrion Healthcare in 2009 as distribution channels were opened in the Americas, Oceania and Europe, followed by Japan, the CIS, Eastern Europe and the Middle East in 2010 and additional European partners in 2013. Remsima was approved by Korea's MFDS in July 2012 and by the EMA in September 2013 as the world's first monoclonal antibody biosimilar, with later approvals for Truxima (EMA 2017, FDA 2018), Herzuma (EMA 2018, FDA 2018), Yuflyma (EMA 2021, FDA 2023) and Vegzelma (EMA and FDA 2022). Celltrion acquired Takeda's primary care assets in 2020, obtained FDA approval for Zymfentra in October 2023, and merged with Celltrion Healthcare on December 28, 2023. In 2024 it established a Vietnamese subsidiary, signed a $72.8 million CDMO deal with Teva for Ajovy, and acquired iQone Healthcare Switzerland; in 2025 it agreed to buy an Eli Lilly drug substance plant in New Jersey, which began operating in January 2026, and in May 2026 it acquired French healthcare company Gifrer. The company's first labour union was established in June 2026.

Risks & controversies

The company's own disclosures cite forward-looking statement risks and, specifically, exposure to US tariffs on imported products, which it addressed by pre-shipping two years of inventory, expanding local CMO contracts and acquiring US manufacturing capacity; regulatory approvals including US merger control were required to close that transaction. A shareholder letter also references the Trump administration's request for drug price reductions. Corporate restructuring has been described as long-delayed, and workers established the company's first union in June 2026.